Pain intensity VAS (0 to 100; 0 = no pain, 100 = worst pain) · Patients with acute low‐back pain
1 finding from 1 review
Disability RMDQ (0 to 24; lower = better) · Patients with acute low‐back pain
1 finding from 1 review
Proportion of participants experiencing global improvement % of dichotomized Likert scale · Patients with acute low‐back pain
NSAIDs may leads to higher proportion of participants experiencing global improvement Various… compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · Patients with acute low‐back pain
It is very uncertain whether NSAIDs changes proportion of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
Return to work · Patients with acute low‐back pain
It is very uncertain whether NSAIDs changes return to work (%) compared with placebo (very low certainty).
1 finding from 1 review
Change in pain intensity from baseline on VAS (0 to 100) short‐term · people with low back pain with sciatica
It is very uncertain whether NSAIDs changes change in pain intensity from baseline on VAS (0 to 100) short‐term compared with placebo (very low certainty).
1 finding from 1 review
Change in disability from baseline to · people with low back pain with sciatica
1 finding from 1 review
Global Improvement short‐term · people with low back pain with sciatica
NSAIDs may leads to higher global Improvement short‐term compared with placebo (low certainty).
1 finding from 1 review
Side effects short‐term · people with low back pain with sciatica
NSAIDs may leads to higher side effects short‐term compared with placebo (low certainty).
1 finding from 1 review
Return to work · Patients with acute low‐back pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in pain intensity from baseline on VAS (0 to 100) short‐term · Patients with acute low‐back pain
1 finding from 1 review
Disability ODI (0 to 50; lower = better) · Patients with acute low‐back pain
1 finding from 1 review
Proportion of participants experiencing global improvement % of dichotomized Likert scale · Patients with acute low‐back pain
1 finding from 1 review
Proportion of participants experiencing adverse events · Patients with acute low‐back pain
It is very uncertain whether selective COX‐2 inhibitors changes proportion of participants experiencing adverse events compared with non‐selective NSAIDs (very low certainty).
1 finding from 1 review